ID 55860
JaLCDOI
FullText URL
72_2_185.pdf 2.55 MB
Author
Morizane, Shin Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sugimoto, Saeko Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Motoki, Takayuki Department of Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Katayama, Norihisa Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Omori, Masako Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwatsuki, Keiji Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.
Keywords
psoriasis
systemic therapy
biologics
malignancy
Amo Type
Case Report
Publication Title
Acta Medica Okayama
Published Date
2018-04
Volume
volume72
Issue
issue2
Publisher
Okayama University Medical School
Start Page
185
End Page
187
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
English
Copyright Holders
CopyrightⒸ 2018 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID